BioCardia (BCDA) Q3 2024 earnings summary

Executive summary

• Advanced clinical-stage cell therapies for cardiovascular and pulmonary diseases, focusing on precision medicine and patient-specific biomarkers, with pivotal trials for heart failure and refractory angina and FDA-cleared delivery devices.

• CardiAMP Heart Failure Trial completed patient follow-up in October 2024; final data and regulatory submissions expected in Q1 2025, with high patient retention and positive interim trends.

• FDA and PMDA consultations ongoing for CardiAMP Cell Therapy System approval in the US and Japan.

• FDA cleared MorphDNA Steerable Introducer product family for market release, with commercial launch set for Q4 2024.

• Completed $7.2 million public offering in September 2024, strengthening cash position and supporting ongoing operations.

Financial highlights

• Q3 2024 net loss was $1.7 million, improved from $2.6 million in Q3 2023, mainly due to lower R&D and SG&A expenses.

• Research and development expenses fell to $931,000 in Q3 2024 from $1.9 million in Q3 2023; SG&A expenses decreased to $825,000 from $1.1 million.

• Revenue for Q3 2024 was $357,000, down from $464,000 for the nine months year-over-year.

• Cash and cash equivalents at September 30, 2024 were $4.9 million, up from $1.1 million at year-end 2023.

• Cash used in operations for the nine months ended September 30, 2024 was $5.5 million, compared to $8.1 million in the prior year period.

Outlook and guidance

• Top-line data from key clinical trials, including CardiAMP Heart Failure and refractory angina, expected in Q1 2025, which may impact regulatory and commercialization timelines.

• CardiAMP Heart Failure II trial protocol amendment expands eligibility and is expected to accelerate enrollment.

• Modest increase in R&D expenses anticipated as trial enrollment ramps up; SG&A expenses projected to remain near current levels.

• Cash burn expected to increase moderately, with current cash insufficient beyond Q2 2025; additional capital will be required.

• Key milestones for Q4 2024 include Japan PMDA consultation, data lock for CardiAMP Heart Failure I, additional site activations, and first commercial MorphDNA product sales.